Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | SHBG | P04278 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10444758 | 1.00 | NR3C1 (0.50) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL11240496 | 0.86 | LMNA (0.68) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL11240498 | 0.86 | LMNA (0.68) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL10868441 | 0.85 | SHBG (0.70) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL10892430 | 0.85 | SHBG (0.70) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL9128581 | 0.82 | SHBG (0.65) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL9128571 | 0.82 | SHBG (0.65) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL15079253 | 0.82 | LMNA (0.49) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL10444770 | 0.82 | LMNA (0.49) | NR3C1LMNAPGRSHBGMEN1 | |
| SCHEMBL15079258 | 0.82 | LMNA (0.49) | NR3C1LMNAPGRSHBGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296780-B2 | Process for alkynylating 16-substituted-17-keto steroids | CRYSTAL PHARMA, S.A.U. (ES) | 2016-03-29 | — | — | US | disclosed |
| US-9296780-B2 | Process for alkynylating 16-substituted-17-keto steroids | CRYSTAL PHARMA, S.A.U. (ES) | 2016-03-29 | — | — | US | disclosed |
| EP-2794632-B1 | PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS | CRYSTAL PHARMA SAU (ES) | 2016-03-16 | — | — | EP | disclosed |
| US-20150005518-A1 | PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS | CRYSTAL PHARMA, S.A.U. (ES) | 2015-01-01 | — | — | US | disclosed |
| US-20150005518-A1 | PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS | CRYSTAL PHARMA, S.A.U. (ES) | 2015-01-01 | — | — | US | disclosed |
| WO-2013092668-A1 | PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005518-A1 | PROCESS FOR ALKYNYLATING 16-SUBSTITUTED-17-KETO STEROIDS | HSD17B7, NR3C2, CYP17A1 | NR3C1 12/4885LMNA 553/4885PGR 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.